Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cognition After Lowering LDL-Cholesterol With Evolocumab
Bariş Gencer, François Mach, Jianping Guo, et al.
Journal of the American College of Cardiology (2020) Vol. 75, Iss. 18, pp. 2283-2293
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Seth S. Martin, Aaron W. Aday, Zaid Almarzooq, et al.
Circulation (2024) Vol. 149, Iss. 8
Open Access | Times Cited: 882
Management of Acute Coronary Syndrome in the Older Adult Population: A Scientific Statement From the American Heart Association
Abdulla A. Damluji, Daniel E. Forman, Tracy Y. Wang, et al.
Circulation (2022) Vol. 147, Iss. 3
Open Access | Times Cited: 158
PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
Maciej Banach, Paweł Burchardt, Krzysztof Chlebus, et al.
Archives of Medical Science (2021) Vol. 17, Iss. 6, pp. 1447-1547
Open Access | Times Cited: 132
Proprotein Convertase Subtilisin/Kexin Type 9
Chiara Macchi, Nicola Ferri, Cesare R. Sirtori, et al.
American Journal Of Pathology (2021) Vol. 191, Iss. 8, pp. 1385-1397
Open Access | Times Cited: 86
Low levels of low-density lipoprotein cholesterol and cognitive decline
Rong Hua, Yanjun Ma, Chenglong Li, et al.
Science Bulletin (2021)
Open Access | Times Cited: 61
There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness
Michael E. Makover, Michael D. Shapiro, Peter P. Tóth
American Journal of Preventive Cardiology (2022) Vol. 12, pp. 100371-100371
Open Access | Times Cited: 59
Contemporary Management of Dyslipidemia
Richard Ferraro, Thorsten M. Leucker, Seth S. Martin, et al.
Drugs (2022) Vol. 82, Iss. 5, pp. 559-576
Open Access | Times Cited: 41
Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association
Larry B. Goldstein, Peter P. Tóth, Jennifer L. Dearborn, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2023) Vol. 43, Iss. 10
Open Access | Times Cited: 38
Vascular cognitive impairment and dementia: Mechanisms, treatment, and future directions
Vincent Mok, Cai Yuan, Hugh S Markus
International Journal of Stroke (2024) Vol. 19, Iss. 8, pp. 838-856
Closed Access | Times Cited: 9
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
Julius L. Katzmann, Ioanna Gouni‐Berthold, Ulrich Laufs
Frontiers in Physiology (2020) Vol. 11
Open Access | Times Cited: 69
Pleiotropic Effects of PCSK-9 Inhibitors
Marcin Basiak, Michał Kosowski, Marcin Cyrnek, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 6, pp. 3144-3144
Open Access | Times Cited: 41
Safety of PCSK9 inhibitors
Grzegorz Grześk, Bednarska Dorota, Łukasz Wołowiec, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113957-113957
Open Access | Times Cited: 34
Insight into the Evolving Role of PCSK9
Mateusz Maligłówka, Michał Kosowski, Marcin Hachuła, et al.
Metabolites (2022) Vol. 12, Iss. 3, pp. 256-256
Open Access | Times Cited: 32
Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia
M. Doortje Reijman, Anja Schweizer, Amy L. Peterson, et al.
European Journal of Preventive Cardiology (2022) Vol. 29, Iss. 9, pp. 1361-1368
Closed Access | Times Cited: 27
Association between human blood metabolome and the risk of delirium: a Mendelian Randomization study
Chubing Long, Dong Lin, Lieliang Zhang, et al.
Frontiers in Endocrinology (2024) Vol. 14
Open Access | Times Cited: 4
Relationship between plasma lipid and cognitive function in the elderly based on individual's diet and ApoE, CD36, SCARB1 genetic polymorphisms
Xiuwen Ren, Xixiang Wang, Yu Liu, et al.
Gene Reports (2025), pp. 102140-102140
Closed Access
Non-linear associations of serum lipid levels with cognitive decline: findings from the ELSA-Brasil cohort
Naomi Vidal Ferreira, Márcio Sommer Bittencourt, Giuliano Generoso, et al.
Atherosclerosis (2025), pp. 119159-119159
Closed Access
Lipid Dysregulation and Delirium in Older Adults: A Review of the Current Evidence and Future Directions
AnaLee Shaw, Rujia Teng, Toluwani Fasina, et al.
Brain Research Bulletin (2025) Vol. 224, pp. 111299-111299
Open Access
How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors
Barbara Cybulska, Longina Kłosiewicz−Latoszek, Peter E. Penson, et al.
Progress in Cardiovascular Diseases (2020) Vol. 67, pp. 65-74
Open Access | Times Cited: 30
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects ― A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial ―
Anthony Keech, Kazuma Oyama, Peter Sever, et al.
Circulation Journal (2021) Vol. 85, Iss. 11, pp. 2063-2070
Open Access | Times Cited: 24
<p>Safety and Tolerability of PCSK9 Inhibitors: Current Insights</p>
Constantine E. Kosmas, Andreas Skavdis, Andreas Sourlas, et al.
Clinical Pharmacology Advances and Applications (2020) Vol. Volume 12, pp. 191-202
Open Access | Times Cited: 27
PCSK9 deficiency alters brain lipid composition without affecting brain development and function
Angela Pärn, Ditte Olsen, Jürgen Tuvikene, et al.
Frontiers in Molecular Neuroscience (2023) Vol. 15
Open Access | Times Cited: 8
PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort
Juan Vicente-Valor, Xandra García‐González, Sara Ibáñez-García, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112519-112519
Open Access | Times Cited: 19
Elevated HDL Levels Linked to Poorer Cognitive Ability in Females With Parkinson’s Disease
Megan C. Bakeberg, Anastazja M. Gorecki, Jade E. Kenna, et al.
Frontiers in Aging Neuroscience (2021) Vol. 13
Open Access | Times Cited: 18
Efficacy and Safety of Lipid-Lowering Drugs of Different Intensity on Clinical Outcomes: A Systematic Review and Network Meta-Analysis
Wenrui Ma, Qinyuan Pan, Defeng Pan, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top